Zhejiang Taimei Medical Technology Co Ltd Class H (2576) AI Stock Analysis

• Market Cap: HK$2.72B
• Dividend Yield: N/A
• Average Volume (3M): 69.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 627
• Sector: Healthcare
• Sector Strength: 45
• Industry: Software - Application
• EPS (TTM): N/A
• Shares Outstanding: 200,592,530
• 10 Day Avg. Volume: 105,560
• 30 Day Avg. Volume: 69,380
• PEG Ratio: 0.28
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 4.11
• P/FCF Ratio: -10.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$4.50
• Price Target Upside: -6.83% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: HK$4.50 ▼(-6.83% Downside)

The overall stock score of 51 reflects significant financial performance challenges, with persistent losses and negative cash flows being the primary concerns. Technical analysis provides mixed signals, indicating short-term stability but lacking clear direction. The absence of valuation metrics adds uncertainty, making it difficult to assess the stock's relative attractiveness. The company's strong equity position offers some stability, but strategic improvements are necessary to enhance financial performance and investor confidence.

Zhejiang Taimei Medical Technology Co Ltd Class H Business Overview & Revenue Model

Company Description

Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders. It offers software solutions, such as eCooperate, a clinical trial cooperation platform that optimizes clinical research operations management systems, as well as support decision-making with big data technology; eArchives, a clinical trial master file system; eCollect, an electronic data capture system; eCollege, a training management system; eQuality, an electronic quality audit system; eBalance, an interactive Web-based response system; eVisit Patient Reported Outcomes, a solution that enhances the ability of patients to enter data and the accuracy of clinical trial data; eTime, a project man-hour management system; and eImage, a medical image reading system. It also provides hospital software, including eTrial, a phase I ward management system; eSite, a clinical trial management system for GCP sites; GCP-X, an intelligent clinical trial platform; NomenCTMS, a clinical research project management system for GCP sites; eScreening, a subject information management and duplicate checking system; Intelligent Investigator, an initiated clinical trial platform; IIT-EDC, a clinical research data management platform; and Investigator-Initiated Clinical Trial Management System, a project management system. In addition, the company offers pharmacovigilance software solutions, such as eSafety global pharmacovigilance system; eSafety, an intelligent professional information system for pharmacovigilance; and SAE Manager, a safety data communication and management system for clinical trials. Further, it provides marketing software and digital innovation solutions. The company was founded in 2013 and is headquartered in Jiaxing, China.

How the Company Makes Money

Zhejiang Taimei Medical Technology Co Ltd generates revenue primarily through the sale of its medical devices and diagnostic products to hospitals, clinics, and other healthcare providers. The company may also engage in long-term service contracts and maintenance agreements for its equipment, providing a steady stream of revenue from service fees. Additionally, Zhejiang Taimei might form strategic partnerships with other healthcare companies to expand its market reach and enhance its product offerings, further contributing to its revenue. These partnerships can also involve joint ventures or co-development agreements that leverage shared expertise and resources.

Zhejiang Taimei Medical Technology Co Ltd Class H Financial Statement Overview

Summary

Zhejiang Taimei Medical Technology Co Ltd Class H faces significant profitability challenges as evidenced by sustained losses and negative cash flows. While cost management has improved gross margins, the company struggles with operational efficiency. The strong equity position provides some stability, but the inability to generate positive returns and cash flows poses risks. Strategic improvements are needed to enhance financial performance.

Income Statement

The company has experienced a declining revenue trend with a 3.83% decrease in 2024 after a slight increase in 2023. Gross profit margin improved to 38.19% in 2024 from 31.23% in 2023, indicating better cost management. However, persistent negative EBIT and net profit margins highlight ongoing operational challenges.

Balance Sheet

The debt-to-equity ratio remains low due to minimal debt levels, reflecting a conservative leverage strategy. Stockholders' equity constitutes a significant portion of total assets, maintaining an equity ratio of 73.09% in 2024. However, the substantial net losses impact the return on equity, indicating inefficiencies in generating returns from shareholder investments.

Cash Flow

Negative operating cash flow persists, though free cash flow improved slightly in 2024. The operating cash flow to net income ratio remains negative, reflecting cash flow challenges linked to profitability. Despite improved capital expenditure management, the overall cash flow position highlights liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	132.05M	551.16M	573.14M	549.22M	466.18M
Gross Profit	49.52M	224.94M	179.00M	185.40M	163.59M
EBITDA	-104.94M	-176.73M	-302.97M	-364.38M	-440.39M
Net Income	-116.28M	-214.61M	-346.78M	-412.91M	-479.61M
Balance Sheet
Total Assets	1.34B	1.58B	1.44B	1.83B	1.80B
Cash, Cash Equivalents and Short-Term Investments	978.70M	1.20B	1.07B	1.41B	1.40B
Total Debt	13.71M	34.76M	15.09M	45.86M	77.44M
Total Liabilities	322.13M	348.62M	402.56M	441.97M	393.75M
Stockholders Equity	942.04M	1.16B	978.33M	1.31B	1.41B
Cash Flow
Free Cash Flow	-113.03M	-207.30M	-360.64M	-357.44M	-249.94M
Operating Cash Flow	-112.56M	-201.62M	-351.16M	-329.22M	-217.53M
Investing Cash Flow	297.63M	-283.68M	237.69M	-5.88M	-379.35M
Financing Cash Flow	-4.42M	281.04M	-39.28M	285.59M	-40.08M

Zhejiang Taimei Medical Technology Co Ltd Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2576, the sentiment is Positive. The current price of 4.83 is above the 20-day moving average (MA) of 4.51, above the 50-day MA of 4.67, and above the 200-day MA of 4.07, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 59.56 is Neutral, neither overbought nor oversold. The STOCH value of 89.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2576.

Zhejiang Taimei Medical Technology Co Ltd Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$384.46M	12.06	―	7.08%	-2.88%	-21.65%
1612	74 Outperform	HK$623.49M	6.99	11.96%	4.32%	17.93%	36.82%
1419	55 Neutral	HK$299.85M	11.38	―	3.54%	9.07%	8.95%
2576	51 Neutral	HK$2.72B	―	―	―	―	―
0557	49 Neutral	HK$351.10M	-11.08	-17.59%	―	-43.78%	-118.13%
3390	49 Neutral	HK$277.14M	-9.66	0.68%	22.58%	-1.68%	-111.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Zhejiang Taimei Medical Technology Co Ltd Class H Corporate Events

Zhejiang Taimei Medical Technology Reports Improved Operational Efficiency Amid Revenue Decline

Zhejiang Taimei Medical Technology Co., Ltd. reported a decrease in revenue and gross profit for the first half of 2025 compared to the same period in 2024, with revenue dropping by 10.5% and gross profit by 9.7%. Despite the decline in revenue, the company significantly reduced its operating loss by 74.6% and its loss for the period by 83.3%, indicating improved operational efficiency and cost management.

The most recent analyst rating on (HK:2576) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Zhejiang Taimei Medical Technology Co Ltd Class H stock, see the HK:2576 Stock Forecast page.

Zhejiang Taimei Medical Technology Schedules Board Meeting for Interim Results

Zhejiang Taimei Medical Technology Co., Ltd. has announced that its board of directors will meet on August 28, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for an interim dividend, which could impact the company’s financial strategy and shareholder returns.

Zhejiang Taimei Medical Technology Announces CFO Transition

Zhejiang Taimei Medical Technology Co., Ltd. has announced a change in its executive team, specifically the resignation of Mr. Jiang Chengwen as Chief Financial Officer, effective July 25, 2025, due to personal commitments. Mr. Wang Wei has been appointed as the new CFO, bringing over a decade of experience in financial management and capital markets, which is expected to strengthen the company’s strategic financial planning and execution capabilities.